Drugs / CVT-E002
CVT-E002
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00435968 | Mar → Jul 2007 | — | CV Technologies | Completed | No outcome recorded |
| Phase 2 | NCT00255307 | Nov 2005 → Apr 2006 | respiratory tract infectious disorder | CV Technologies | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00259831 | Dec 2005 → Jun 2006 | respiratory tract infectious disorder | CV Technologies | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVT E002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00435968 ↗ |
| Known as | Cold-FX | “CVT-E002 (Cold-FX); a natural health product” NCT00259831 ↗1“CVT E002 (Cold-fX)” NCT00435968 ↗ |
| Known as | ginseng extract | “CVT-E002 ginseng extract” NCT00255307 ↗ |
| Modality | Other / unclassified | “a natural health product” NCT00259831 ↗ |
| Route | Oral | “receive an oral aqueous solution” NCT00255307 ↗ |